Sagility Stock Surges 8% as Nomura Initiates 'Buy' Call

Sagility Shares Rally on Positive Brokerage Report

Shares of mid-cap IT services firm Sagility experienced a significant rally on Wednesday, climbing as much as 8% to reach an intraday high of ₹40.29. The surge in investor interest came after the global brokerage firm Nomura initiated coverage on the stock with a 'Buy' recommendation. This positive trigger provided a much-needed boost to the stock, which had touched its 52-week low just last week.

By mid-day, the shares were trading around the ₹39.68 mark, maintaining a gain of over 6%. The renewed optimism is directly linked to Nomura's bullish outlook, which projects a substantial upside for the healthcare-focused technology provider.

Nomura's Target Price and Rationale

Nomura has set a target price of ₹55 per share for Sagility. This target implies a potential upside of approximately 47.4% from its current market price. The brokerage's confidence stems from its belief that Sagility is uniquely positioned to benefit from the ongoing transformation in the US healthcare services sector, which is increasingly driven by artificial intelligence (AI).

According to Nomura's analysis, healthcare companies are shifting away from short-term, transactional services towards long-term, outcome-focused solutions. This strategic shift favors specialized firms like Sagility, which possess deep domain expertise across the entire healthcare value chain, over providers offering only isolated solutions.

AI as a Key Growth Catalyst

The increasing adoption of AI and automation is a primary driver of Sagility's growth potential. While engagement services, which account for about 30% of Sagility's revenue, are less likely to be impacted by automation due to the complex and highly regulated nature of the healthcare industry, AI tools are expected to enhance operational efficiency significantly. Technologies like generative AI and analytics-powered agent assistance can improve productivity and streamline processes.

However, Nomura notes that a substantial portion of these cost savings, estimated to be around 70-80%, will likely be passed on to clients. This strategy is expected to help maintain stable margins for Sagility over the medium term while strengthening client relationships.

Strong Business Fundamentals

Sagility operates as a pure-play, technology-enabled healthcare solutions provider, with a primary focus on the US market. Its revenue is predominantly generated from payers (US health insurance companies), which contribute about 90% of its income, while providers (hospitals) account for the remaining 10%.

The company has built a stable and loyal client base. As of the third quarter of FY26, Sagility served 81 client groups, boasting an impressive average client relationship tenure of 18 years and a client retention rate of 95%. This demonstrates the company's ability to deliver high-quality, integrated solutions that are critical to its clients' operations.

Financial Projections and Market Outlook

Nomura projects robust growth for Sagility in the coming years. The brokerage forecasts a Compound Annual Growth Rate (CAGR) of 12% for revenue in US dollar terms and a 20% CAGR for Earnings Per Share (EPS) in Indian rupee terms between FY26 and FY28. This growth is supported by the broader expansion of the US healthcare operations outsourcing market, which is expected to grow at a CAGR of 6-8% for the payer segment and 11-13% for the provider segment through 2028.

Institutional Investors Show Confidence

Recent shareholding patterns indicate growing confidence from institutional investors. Domestic Institutional Investors (DIIs) have steadily increased their stake in the company, rising from 7.25% in December 2024 to 21.35% by December 2025. Similarly, Foreign Institutional Investors (FIIs) have also increased their holdings, which grew to 10.25% by December 2025, signaling strong institutional backing.

Identified Risks and Challenges

Despite the positive outlook, Nomura has highlighted several potential risks that could impact Sagility's performance. These include a potential slowdown in the US healthcare payer industry, a reduction in the outsourcing of operational tasks, disruptions to existing business models from new technologies, and increased competition from new market entrants. Investors should consider these factors when evaluating the company's prospects.

Conclusion

The 'Buy' rating from Nomura has provided a significant positive catalyst for Sagility's stock, which had been underperforming in recent months. The company's deep expertise in the US healthcare sector, combined with the tailwinds from AI adoption, positions it well for future growth. While risks remain, the strong financial projections and increasing institutional interest suggest a favorable outlook for the company as it navigates the evolving healthcare landscape.